Company Analysis
Sign in

argenx SE (ARGX)

Nasdaq: ARGX · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2017
Full chart Alerts Compare
Grade6.3
◀ Past 5.5● Present 6.3▶ Future 7.1
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2023, as filed
Revenue$35.5M+254.4%
Net income-$295M+58.4%
Earnings per share$-5.16+60.5%
Operating cash flow-$420M+51.3%
Cash$2.05B+155.9%
Debt$7.2M
Shareholders’ equity$4.10B+45.6%
Shares, diluted57.2M+5.1%
Return on equity17.6%
The recordfrom its filings
Filings in 202635
Newest filingNov 9 · 6-K
Annual reportMar 19, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted10
Filer categoryLarge accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
1819202122232425
As filed, in USD. Nothing here is a forecast.

News

Aug 27, 2026 · SEC EDGAR · Form SC TO-T/A
Tender offer, amended
Open the filing on sec.gov
Aug 19, 2026 · SEC EDGAR · Form SC TO-T/A
Tender offer, amended
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton ARGX · research, not advice